Eagle Biosciences

Eagle Biosciences

Pre-clinical
Amherst, United StatesFounded 2005eaglebio.com

Eagle Biosciences operates as a specialized distributor and developer of critical life science research tools, primarily ELISA kits and MHC reagents. The company has established itself through a 'boutique approach,' actively sourcing and providing unique, high-quality products from various suppliers to meet specific researcher needs. Its core offerings support drug development, particularly in the booming biologics and immunotherapy space, by enabling precise measurement of drug concentrations and immune responses. Eagle Biosciences positions itself as a problem-solving partner for researchers who cannot find specific assays elsewhere.

Market Cap
Private
Pipeline
Patents
Publications

Private Company

Total funding raised: $14.5M

AI Company Overview

Eagle Biosciences operates as a specialized distributor and developer of critical life science research tools, primarily ELISA kits and MHC reagents. The company has established itself through a 'boutique approach,' actively sourcing and providing unique, high-quality products from various suppliers to meet specific researcher needs. Its core offerings support drug development, particularly in the booming biologics and immunotherapy space, by enabling precise measurement of drug concentrations and immune responses. Eagle Biosciences positions itself as a problem-solving partner for researchers who cannot find specific assays elsewhere.

ImmunologyOncologyNeurologyMetabolic DiseasesCardiologyNephrologyGastroenterologyInfectious DiseaseEndocrinology

Technology Platform

A curated portfolio of research assay technologies, primarily ELISA (Enzyme-Linked Immunosorbent Assay) kits and customizable MHC-peptide complexes (easYmers®), sourced from various manufacturers to support drug development and life science research.

Funding History

2
Total raised:$14.5M
Series A$12MNov 15, 2020
Seed$2.5MJun 15, 2018

Opportunities

Growth is driven by the expanding market for biologics and biosimilars, which increases demand for therapeutic drug monitoring and anti-drug antibody assays.
The rise of personalized medicine and immunotherapy research also creates significant opportunities for their specialized immunology tools like customizable MHC tetramers.

Risk Factors

Key risks include dependence on third-party suppliers for products, intense competition from larger reagent distributors with greater scale, and sensitivity to fluctuations in global life sciences R&D funding.
A lack of proprietary, patented technology platforms could limit long-term defensibility.

Competitive Landscape

Eagle competes with large, diversified life science suppliers like Thermo Fisher and Merck KGaA, as well as specialized assay developers. Its differentiation lies in a 'boutique' sourcing model focused on finding unique, hard-to-source products and providing personalized customer service, positioning it as a partner rather than just a vendor.